CardioExchange Archive

February 25th, 2013

Selections from Richard Lehman’s Literature Review: February 25th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.

---

February 22nd, 2013

SYNTAX After 5 Years: Any Change in Results (or Your Practice)?

Richard A. Lange, MD, MBA and L. David Hillis, MD

The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published.  SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of […]

---

September 13th, 2010

Three-year SYNTAX Results: Sensible, Not Sensational

Richard A. Lange, MD, MBA

In SYNTAX, 1800 patients with multivessel and/or left main disease were randomized to CABG or PCI with DES after a surgeon and an interventional cardiologist reviewed the coronary angiogram and agreed that either procedure was appropriate. (See the CardioExchange News blog for more study information.) The SYNTAX 3-year results show that patients with a low SYNTAX […]

---

September 13th, 2010

SYNTAX at 3 years: CABG Still Winning, but PCI Acceptable in Low-Risk Patients

Larry Husten, PHD

Three-year outcomes from the SYNTAX trial continue to show the overall superiority of CABG over PCI in patients with complex disease, but they leave room for the use of PCI in patients with low-risk disease. The results of the trial were presented by A. Pieter Kappetein at the European Association of Cardio-Thoracic Surgery annual meeting in Geneva, Switzerland. […]

---